Recombinant Human GBA/Glucosylceramidase Protein，His & SUMO

Glucosylceramidase (GBA) is an important lysosomal enzyme responsible for the hydrolysis of glucocerebrosides into glucose and ceramide, playing a crucial role in lipid metabolism. Deficiency in GBA activity leads to the accumulation of glucocerebrosides, a condition prominently associated with Gaucher's disease, the most common lysosomal storage disorder. The importance of GBA has gained attention not only due to its relevance in Gaucher's disease but also for its potential links to other neurodegenerative diseases, such as Parkinson's disease, where mutations in the GBA gene have been identified as significant risk factors. The advancement of molecular biology techniques has facilitated the generation of recombinant GBA proteins, enabling detailed studies of enzyme function, regulation, and interaction with small molecule therapeutics. These recombinant proteins serve as valuable tools for developing enzyme replacement therapies, which aim to restore the deficient enzymatic activity in patients. Furthermore, characterizing the structural and functional properties of GBA is essential for understanding its role in disease pathology and for designing novel therapeutic strategies that can address the underlying molecular defects. The ongoing research into recombinant GBA not only contributes to therapeutic advances for Gaucher's disease but also provides insights into broader implications for lysosomal function and neurodegeneration.